Your browser doesn't support javascript.
loading
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
Penson, David F; Armstrong, Andrew J; Concepcion, Raoul S; Agarwal, Neeraj; Olsson, Carl A; Karsh, Lawrence I; Dunshee, Curtis J; Duggan, William; Shen, Qi; Sugg, Jennifer; Haas, Gabriel P; Higano, Celestia S.
Afiliação
  • Penson DF; Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. david.penson@vumc.org.
  • Armstrong AJ; Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
  • Concepcion RS; The Comprehensive Prostate Center, Nashville, TN, USA.
  • Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Olsson CA; Accumed Research Associates, Garden City, NY, USA.
  • Karsh LI; The Urology Center of Colorado, Denver, CO, USA.
  • Dunshee CJ; Urological Associates of Southern Arizona, Tucson, AZ, USA.
  • Duggan W; Global Product Development, Pfizer Inc., Groton, CT, USA.
  • Shen Q; Global Product Development, Pfizer Inc., Collegeville, PA, USA.
  • Sugg J; Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA.
  • Haas GP; Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.
  • Higano CS; Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Prostate Cancer Prostatic Dis ; 25(3): 597, 2022 Sep.
Article em En | MEDLINE | ID: mdl-34848822
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article